TIR domain-containing adaptor protein (TIRAP)

TIR domain-containing adaptor protein (abbreviated TIRAP, also known as MAL) is a key adaptor molecule in the Toll-like receptor (TLR) signaling pathway, primarily acting as a bridge between TLR2 and TLR4 (after recognition of pathogenic ligands such as bacterial lipopolysaccharide) and downstream effectors including MyD88. TIRAP facilitates the activation of pathways leading to transcription factors such as NF-κB and MAP kinases, resulting in cytokine secretion and the initiation of the inflammatory response[1][2][3][7][8]. TIRAP contains a TIR (Toll/interleukin-1 receptor) domain that mediates homotypic and heterotypic interactions with other TIR domain-containing proteins. While essential for host defense, its aberrant activation contributes to inflammatory and autoimmune disease. TIRAP/Human MAL is not known to be a direct target of any approved therapeutic drugs but is a subject of drug discovery efforts and genetic association studies for infection and inflammatory disease susceptibility[1][7].

Other names

Toll/interleukin-1 receptor domain-containing adaptor proteinMyD88 adaptor-like proteinMAL

Drugs or molecules targeting TIRAP would generally modulate TLR-mediated signaling, altering inflammatory cytokine production and innate immune responses[1][7].